May 28 (Reuters) - Genmab A/S:
* REG-GENMAB ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN LIGHT-CHAIN (AL) AMYLOIDOSIS
* GENMAB - PHASE III ANDROMEDA STUDY OF DARATUMUMAB IN LIGHT-CHAIN (AL) AMYLOIDOSIS MET PRIMARY ENDPOINT OF PATIENTS WITH HEMATOLOGIC COMPLETE RESPONSE
* GENMAB - STUDY, CONDUCTED BY JANSSEN BIOTECH MET PRIMARY ENDPOINT OF PERCENTAGE OF PATIENTS WITH HEMATOLOGIC COMPLETE RESPONSE
* GENMAB - JANSSEN WILL DISCUSS DATA WITH HEALTH AUTHORITIES TO PREPARE FOR REGULATORY FILINGS Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.